156 related articles for article (PubMed ID: 19857794)
21. Ultrase and Viracept.
Fornataro K; Jefferys R
Body Posit; 1999 Oct; 12(10):10. PubMed ID: 11366873
[TBL] [Abstract][Full Text] [Related]
22. MNT and MutaMouse studies to define the in vivo dose response relations of the genotoxicity of EMS and ENU.
Gocke E; Ballantyne M; Whitwell J; Müller L
Toxicol Lett; 2009 Nov; 190(3):286-97. PubMed ID: 19446969
[TBL] [Abstract][Full Text] [Related]
23. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
Reeve LM
Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
[TBL] [Abstract][Full Text] [Related]
24. European license for Viracept re-established by EC.
AIDS Patient Care STDS; 2007 Nov; 21(11):891. PubMed ID: 18338433
[No Abstract] [Full Text] [Related]
25. Viracept recommended for reinstatement in Europe.
AIDS Patient Care STDS; 2007 Oct; 21(10):780. PubMed ID: 17992722
[No Abstract] [Full Text] [Related]
26. Drug safety in pregnant women and their babies: ignorance not bliss.
Chambers CD; Polifka JE; Friedman JM
Clin Pharmacol Ther; 2008 Jan; 83(1):181-3. PubMed ID: 18073777
[TBL] [Abstract][Full Text] [Related]
27. Provision of information on regulatory authorities' websites.
Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
[TBL] [Abstract][Full Text] [Related]
28. Protease inhibitor therapy in resource-limited settings.
Elliott JH; Pujari S
Curr Opin HIV AIDS; 2008 Nov; 3(6):612-9. PubMed ID: 19373032
[TBL] [Abstract][Full Text] [Related]
29. Final report on the safety assessment of HC Red No. 7.
Cosmetic Ingredient Review Expert Panel
Int J Toxicol; 2008; 27 Suppl 1():45-54. PubMed ID: 18569161
[TBL] [Abstract][Full Text] [Related]
30. Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substance.
Bercu JP; Hoffman WP; Lee C; Ness DK
Regul Toxicol Pharmacol; 2008 Aug; 51(3):270-7. PubMed ID: 18550240
[TBL] [Abstract][Full Text] [Related]
31. Toxicity of HIV protease inhibitors: clinical considerations.
Boesecke C; Cooper DA
Curr Opin HIV AIDS; 2008 Nov; 3(6):653-9. PubMed ID: 19373038
[TBL] [Abstract][Full Text] [Related]
32. Clinical pharmacology of HIV protease inhibitors in pregnancy.
van der Lugt J; Colbers A; Burger D
Curr Opin HIV AIDS; 2008 Nov; 3(6):620-6. PubMed ID: 19373033
[TBL] [Abstract][Full Text] [Related]
33. European biologicals registers: methodology, selected results and perspectives.
Zink A; Askling J; Dixon WG; Klareskog L; Silman AJ; Symmons DP
Ann Rheum Dis; 2009 Aug; 68(8):1240-6. PubMed ID: 18647854
[TBL] [Abstract][Full Text] [Related]
34. Caution regarding nelfinavir use in children and pregnant women.
AIDS Clin Care; 2007 Nov; 19(11):96. PubMed ID: 18399001
[TBL] [Abstract][Full Text] [Related]
35. The legal standards for the radioactive or non radioactive drugs research and approval in the European Community and in Germany after the thalidomide catastrophe.
Barsch M; Otte A
Hell J Nucl Med; 2010; 13(1):45-51. PubMed ID: 20411171
[TBL] [Abstract][Full Text] [Related]
36. Saquinavir, the pioneer antiretroviral protease inhibitor.
la Porte CJ
Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1313-22. PubMed ID: 19737048
[TBL] [Abstract][Full Text] [Related]
37. Recall of AIDS drug hits world's poorest patients.
AIDS Read; 2007 Sep; 17(9):439. PubMed ID: 17902224
[No Abstract] [Full Text] [Related]
38. The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s).
Dorato MA; Engelhardt JA
Regul Toxicol Pharmacol; 2005 Aug; 42(3):265-74. PubMed ID: 15979222
[TBL] [Abstract][Full Text] [Related]
39. Estimation of acute oral toxicity using the No Observed Adverse Effect Level (NOAEL) from the 28 day repeated dose toxicity studies in rats.
Bulgheroni A; Kinsner-Ovaskainen A; Hoffmann S; Hartung T; Prieto P
Regul Toxicol Pharmacol; 2009 Feb; 53(1):16-9. PubMed ID: 18977273
[TBL] [Abstract][Full Text] [Related]
40. Reichardt's dye and its reactions with the alkylating agents 4-chloro-1-butanol, ethyl methanesulfonate, 1-bromobutane and Fast Red B - a potentially useful reagent for the detection of genotoxic impurities in pharmaceuticals.
Corrigan DK; Whitcombe MJ; McCrossen S; Piletsky S
J Pharm Pharmacol; 2009 Apr; 61(4):533-7. PubMed ID: 19298702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
